LifeStance Health Group (NASDAQ:LFST) COO Lisa Miller Sells 47,912 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) COO Lisa Miller sold 47,912 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the transaction, the chief operating officer directly owned 281,289 shares in the company, valued at $3,051,985.65. The trade was a 14.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

LifeStance Health Group Stock Up 6.3%

Shares of LFST traded up $0.73 during trading hours on Wednesday, reaching $12.23. The stock had a trading volume of 6,069,213 shares, compared to its average volume of 3,433,701. The firm has a 50-day simple moving average of $10.10 and a 200 day simple moving average of $8.12. LifeStance Health Group, Inc. has a 12 month low of $4.77 and a 12 month high of $12.43. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $4.74 billion, a price-to-earnings ratio of 94.08 and a beta of 1.14.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The business had revenue of $435.35 million during the quarter, compared to analyst estimates of $414.58 million. During the same quarter in the previous year, the business posted ($0.01) EPS. LifeStance Health Group’s quarterly revenue was up 26.1% on a year-over-year basis. Equities research analysts predict that LifeStance Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Institutional Trading of LifeStance Health Group

Several institutional investors have recently made changes to their positions in the company. Royal Bank of Canada raised its holdings in shares of LifeStance Health Group by 63.4% in the first quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock valued at $468,000 after purchasing an additional 27,244 shares during the last quarter. AQR Capital Management LLC boosted its position in LifeStance Health Group by 223.0% in the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after purchasing an additional 35,554 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in LifeStance Health Group by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock valued at $952,000 after acquiring an additional 4,169 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of LifeStance Health Group by 1.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock worth $4,100,000 after acquiring an additional 11,331 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in LifeStance Health Group by 10.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company’s stock valued at $2,847,000 after acquiring an additional 51,154 shares during the period. Institutional investors own 85.50% of the company’s stock.

Wall Street Analysts Forecast Growth

LFST has been the subject of several recent research reports. Weiss Ratings reissued a “hold (c-)” rating on shares of LifeStance Health Group in a research report on Wednesday, May 27th. Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. KeyCorp boosted their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Barclays boosted their price objective on LifeStance Health Group from $9.00 to $13.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. Finally, Wall Street Zen lowered LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, LifeStance Health Group has an average rating of “Moderate Buy” and a consensus target price of $11.62.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.